US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

argenx SE - American Depositary Shares (NQ:ARGX)

919.21 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
A Bearish Sign Appears On argenx's Chart ↗
 
Via Benzinga
News headline image
Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment ↗
 
Via Benzinga
News headline image
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
5 Analysts Have This to Say About argenx ↗
 
Via Benzinga
News headline image
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
Earnings Outlook For argenx ↗
 
Via Benzinga
Analyst Ratings for argenx ↗
 
Via Benzinga
Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
argenx Announces Planned Transition of Chief Operating Officer
From argenx SE
Via GlobeNewswire
News headline image
argenx Appoints Steve Krognes to Board of Directors
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
From argenx SE
Via GlobeNewswire
News headline image
Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗
 
Via Benzinga
Expert Ratings for argenx ↗
 
Via Benzinga
News headline image
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
News headline image
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via GlobeNewswire
News headline image
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... 
Via Benzinga
News headline image
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday ↗
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading. 
Via Benzinga
News headline image
argenx Appoints Ana Cespedes to Board of Directors
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
News headline image
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position ↗
 
Via Benzinga
News headline image
argenx Enters Into Agreement To Acquire Priority Review Voucher
From argenx SE
Via GlobeNewswire
News headline image
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review ↗
 
Via Benzinga
News headline image
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
From argenx SE
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >